Posted by Michael Wonder on 16 Sep 2021
With remdesivir, the Federal Joint Committee assesses the additional benefit of an anti-viral COVID-19 drug for the first time
16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated with the anti-viral agent remdesivir (Veklury)?
The Federal Joint Committee (G-BA) pursued this question in its benefit assessment and examined the advantages of remdesivir over the therapeutic alternatives.
At today's meeting, the G-BA came to a differentiated result: adult COVID patients whose pneumonia is not yet very severe can benefit from treatment with remdesivir. However, due to uncertainties regarding the therapeutic alternatives used and the partly heterogeneous study situation, the extent of the additional benefit is classified as only minor.
